Search Results - Srikumar Sahasranaman

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy

    Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy by Lucy Lee, Manish Gupta, Srikumar Sahasranaman

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

    Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development by Anand Rotte, Srikumar Sahasranaman, Nageshwar Budha

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

    A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia by Thomas J. Kipps, Herbert Eradat, Sebastian Grosicki, John Catalano, Walter Cosolo, Iryna Dyagil, Sreeni Yalamanchili, Akiko Chai, Srikumar Sahasranaman, Elizabeth A. Punnoose, Deborah Hurst, Halyna Pylypenko

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact

    Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact by Yu Tian, Chi‐Yuan Wu, Srikumar Sahasranaman, Xianbin Tian, Ying Fei Li, Zhiyu Tang, Yanfei Yang, Ya Wan, Quting Zhang, Patrick Schnell, Ariadna Mendoza‐Naranjo, Ramil Abdrashitov, William D. Hanley, Nageshwar Budha

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors by Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel‐Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine Murray, Jennifer L. Schutzman, Jennifer Lauchle, Jean‐Charles Soria, Patricia LoRusso

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: